articleThe LancetOct 31, 2013Closed access

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

JLJeffrey L. CummingsSIStuart IsaacsonRMRoger MillsHWHilde WilliamsKCKathy Chi‐Burris

Lou Ruvo Brain Institute · Cleveland Clinic · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

940
total citations
FWCI
26.86
Percentile
100%
References
34
Citations per year

Authors

8

Topics & keywords

Topics
Keywords
  • Placebo
  • Tolerability
  • Medicine
  • Antipsychotic
  • Psychosis
  • Internal medicine
  • Population
  • Adverse effect
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.